|Mr. Bryan M. Reasons||Sr. VP of Fin. & CFO||553.2k||N/A||50|
|Mr. Mark A. Schlossberg||Sr. VP, Gen. Counsel & Corp. Sec.||572.77k||N/A||56|
|Mr. Michael J. Nestor||Pres of Impax Specialty Pharma Division||581.85k||N/A||64|
|Mr. Douglas S. Boothe||Pres of Impax Generics Division||467.2k||N/A||53|
|Mr. Paul M. Bisaro||Pres, CEO & Director||N/A||N/A||56|
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment focuses on the development, sale, and distribution through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.
Impax Laboratories, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 2; Compensation: 9.